Navigation Links
Medco Announces Research Collaboration with FDA Focused on Personalized Medicine

Study to report findings on how genes impact efficacy of many commonly used

prescription medications

FRANKLIN LAKES, N.J., Aug. 18 /PRNewswire-FirstCall/ -- Medco Health Solutions, Inc. (NYSE: MHS), the nation's leading pharmacy benefit manager, announced it and the Food and Drug Administration (FDA) have entered into a research partnership to study genetic testing and the impact of genetics on the efficacy of prescription drugs. The announcement adds credence to the emerging science of personalized medicine and will expand the body of evidence for the consideration of personal genetics in how doctors prescribe drugs.

Under the partnership, Medco and the FDA will jointly develop research projects, programs and strategies in the area of pharmacogenomics, collectively aimed at improving patient health and quality in the delivery of care. Pharmacogenomics is the science of capturing a patient's genetic information to help predict how a person is likely to respond to a wide variety of drugs, including commonly used prescriptions such as pain relievers, anticoagulants, and cancer drugs. This information has a bearing on what drug is selected and may help optimize doses for particular drugs. Commercial tests are currently available to identify the appropriateness of specific drug treatments based upon a patient's genetic profile.

"An increasing number of drugs are including genetic information in their labels and we're finding out how genes affect some drugs that have been widely used for generations," said Medco's Chief Medical Officer Dr. Robert Epstein. "Studying this field can advance pharmacy care to remove some of the trial and error in how medications are prescribed."

Research Partnership

The research agreement extends to Aug. 31, 2010, during which time Medco will deliver a series of reports to the FDA about pharmacogenomic testing. The topics to be studied will address the safety of prescription drugs, physician participation in pharmacogenomics testing, the usefulness of the tests in prescribing, and quantifying prescription information about drugs that have genetic information in their labels. Medco's reports will be derived from clinical settings, including one that will examine whether physicians are willing to change the dose of a prescription based on a genetic test result. Medco's database of pharmacy claims will supply a large portion of the data to be used in the reports for the FDA.

"Medco's partnership with the FDA should help establish gene testing as a tool to help lower health care costs and improve the quality of care," Epstein said. "This will come from reducing waste from treatments that do not work and also from helping prevent unnecessary hospitalizations from incorrect dosages or other adverse drug events."

Medco plans on submitting portions of the research from this partnership to peer-reviewed journals for publication with an eye on building the body of evidence supporting the value of these tests.

Medco has existing research collaborations with Mayo Clinic studying genetic consideration in the use of warfarin, and with LabCorp regarding breast cancer patients using tamoxifen. Completion of the tamoxifen study is expected this year and the warfarin study is anticipated next year. The company anticipates additional development partnerships with private companies, academic institutions and other health care entities.

Pharmacogenomics revolution

Unique differences in an individual's genes can cause variations in how many prescription drugs are metabolized in the body. These differences affect the speed of which a patient metabolizes medication -- affecting safety or efficacy from too high or low of a dose. Such a situation can be dangerous or potentially deadly in the case of common medications like warfarin or codeine. Approximately 30 percent of all medications are metabolized by one enzyme (CYP2D6). This opens up a far reaching range of genetic tests that could be used to determine how people will respond to a wide range of medications, including antidepressants, pain relievers, heartburn treatments, and antihistamines.

About Medco

Medco Health Solutions, Inc. (NYSE: MHS) is the nation's leading pharmacy benefit manager based on its 2007 total net revenues of more than $44 billion. Medco's prescription drug benefit programs, covering approximately one-in-five Americans, are designed to drive down the cost of pharmacy health care for private and public employers, health plans, labor unions and government agencies of all sizes, and for individuals served by the Medicare Part D Prescription Drug Program and those served by its specialty pharmacy segment, Accredo Health Group. Medco, the world's most advanced pharmacy(TM), is positioned to serve the unique needs of patients with chronic and complex conditions through its Medco Therapeutic Resource Centers(R), including its enhanced diabetes pharmacy care practice through the Liberty acquisition. Medco is the highest-ranked independent pharmacy benefit manager on the 2008 Fortune 100 list. On the Net:

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the risks and uncertainties that affect our business, particularly those mentioned in the Risk Factors section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.

SOURCE Medco Health Solutions, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MedCom USAs Subsidiary Card Activation Technologies, Inc.s SB2 Registration Declared Effective by SEC
2. Medco Unveils Three New Medicare Prescription Drug Plan Options for 2008 to Provide Seniors More Choice, Better Value and Specialist Pharmacists
3. Medco Announces Date for Third-Quarter 2007 Financial Results
4. Six Olympic Legends Battling Chronic Diseases Lead Revolution in Advancing Pharmacy Care as Medco Launches the Tour of Champions
5. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
6. Medco to Build Worlds Largest, Most Advanced Automated Pharmacy in Central Indiana
7. Medco Elects Myrtle Potter, William Roper to Board of Directors
8. Medco CEO to Present at the Merrill Lynch & Co., Inc. 2007 Health Services Investor Conference
9. Medco Announces Two-For-One Stock Split
10. URAC Names Medco as a Finalist in First-ever Best Practices in Consumer Empowerment and Protection Awards
11. MedcomSoft appoints former U.S. presidential health advisor, James Haveman, to health Care advisory board
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by ... Chicago, IL, UV Angel is evaluating the efficacy of its product and its disinfection ... (totaling 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic ...
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I saw a passenger ... thought there had to be a convenient and comfortable way to protect them from ... disabled individuals to safely travel during cold or inclement weather. In doing so, it ...
(Date:11/25/2015)... ... , ... Today, Mothers Against Drunk Driving (MADD) learned that the ... the first time since 2011. In 2014, there were 9,967 fatalities involving an alcohol ... National Highway Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in ...
(Date:11/25/2015)... ... 25, 2015 , ... Castlewood Treatment Center for Eating Disorders, ... as a result of the $20,000 raised at the center’s recent golf ... Club in Eureka, will help individuals who otherwise might not seek treatment for ...
(Date:11/25/2015)... ... November 25, 2015 , ... In honor of Pulmonary Hypertension ... and groups responsible for advancing care for pulmonary hypertension (PH) patients and helping ... public, will receive special recognition throughout 2016 as part of PHA’s 25th anniversary ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... HILL, N.C. , Nov. 24, 2015  In ... research projects in an effort to quickly uncover new ... position. --> --> ... launch a market research project and ensure that all ... company and industry standards. Another major barrier to efficiently ...
(Date:11/24/2015)... Nueva York , 24 de noviembre ... fabricante del Avery Breathing Pacemaker System, se complace ... MD; Ph.D. como consultor clínico. ... --> Foto -   ... doctor Jonzon es un fisiólogo y consultor en ...
(Date:11/24/2015)... Nov. 24, 2015  DILON Diagnostics and GE Healthcare ... agreement for DILON to distribute GE,s Discovery NM750b Molecular ... signing of this distribution agreement will provide Dilon,s experienced ... Imaging system and is considered an initial step in ... solutions for clinicians and their patients. ...
Breaking Medicine Technology: